

RECORDATI: SHAREHOLDERS AGREEMENTS

Milan, 4th July 2018 - In fulfilment of the requirements of article 129 of Consob Regulation 11971/99, here attached are the extracts of the shareholders agreements relating to Recordati S.p.A. that have been published by their underwriters today in the daily newspaper "MF" as well as on the Company's website (www.recordati.com).

In addition, the essential information on the above-mentioned shareholders agreements pursuant to Art. 122 of Legislative Decree n. 58/1998 and art. 130 Consob Regulation 11971/99 are available on the Company's website (www.recordati.com).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Marianne Tatschke (39)0248787393

(39)0276004736, (39)0276004745 e-mail: investorelations@recordati.it

e-mail: norismorano@studionorismorano.com

Media Relations

Studio Noris Morano